Targeting Resistance in EGFRm NSCLC with HER3-Directed ADCs in the Community Setting

Chairperson Perspective: Practice-Changing Strategies in Community Care Settings for Patients with CLL/SLL and MCL

Improving Outcomes and Addressing Racial Disparities in Patients With HR+/HER2- Early Breast Cancer: A Case-Based Learning Lab 

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: Cytogenetic Testing and PARP Inhibition for Maintenance Treatment 

Improving Interprofessional Management and Clinical Outcomes with PARP Inhibitors for Advanced Ovarian Cancer: PARP Inhibitor-Related Adverse Events and Team-Based Care

Chairperson's Perspective: Novel Treatments for Newly Diagnosed Ph+ CML-CP: Striking the Balance of Treatment With Patient Goals and QoL

Advancing ALK Inhibition Into Early-Stage NSCLC: Integrating Biomarker-Driven Therapies to Reduce Recurrence Risk Post Resection

Chairperson's Perspective: Redefining Treatment Across the Spectrum of HR+/HER2-Expressing Metastatic Breast Cancer

Chairperson Perspective: Precision Payloads: Exploring ADC-Directed Therapies in HER2-Mutant and Overexpressing Lung Cancer

CD20 X CD3 Bispecifics—Redefining Treatment for Patients with R/R DLBCL/LBCL in the Community Setting